Rare Disease Treatment Market 2020 By Regional Trend & Growth Forecast To 2026

Rare Disease Treatment Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

The global rare disease treatment industry has experienced substantial growth in recent years, driven by favorable government initiatives and a number of new drug launches. The occurrence of rare disorders worldwide has increased rapidly over the years.

The National Institutes of Health (NIH) reports that nearly 30 million Americans suffer from one of the 7,000 rare health problems, of which only 5% disorders have treatments. As a result, the need for novel therapeutic drugs and treatments is greater than ever. Research and development on rare disease characteristics is gathering pace with the emergence of new rare genetic disorders caused by radiation exposure.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/3873

According to a research report by GMI, global rare disease treatment market size is slated to surpass US$317 billion by 2026.

With respect to route of administration, in 2019, the oral route of administration segment held a considerable market share and exceeded a valuation of more than $80.2 billion. Oral route of administration is highly preferred for consumption of drug since it is convenient, cost-effective, and non-invasive in comparison to other injectable administration. The segment is also driven by the additional benefits associated with the administration method, such as ease of ingestion, and safety of patients. Consequently, preference for the oral route of administration is rapidly increasing among patients, which would effectively lead to substantial development of novel oral drugs.

On the geographical front, Brazil dominated the overall rare disease treatment market in Latin America and is estimated to expand at a CAGR of more than 12.8% over the projected time frame. This anticipated growth is ascribed to the improving public healthcare infrastructure across the country. Regional government authorities are introducing various measures to focus on treatment of rare diseases. The Brazilian Health Authorities (ANVISA) has set up a standard procedure for the approval of clinical trials for the treatment, diagnosis, as well as prevention of rare diseases. In addition, major key players in the country are actively focusing towards the development of new therapeutic drugs. The afore-mentioned factors are likely to fuel the regional rare diseases treatment market growth in the years to come.

At present, prominent industry players are implementing numerous strategic initiatives such as mergers, partnerships, and collaborations in order to expand their offerings and subsequently strengthen their presence in the market. Citing an instance, in November 2020, Evox Therapeutics Ltd, a renowned exosome therapeutics company, reportedly announced the launch of a new collaboration largely focused on rare diseases with the Oxford-Harrington Rare Disease Centre, University of Oxford rooted within the Pediatrics department.

Request for customization @ https://www.gminsights.com/roc/3873

This collaboration would run over a period of three years and would capitalize on the top-class research environment in Oxford, using exosome therapeutics expertise as well as resources from both the University and Evox to fuel innovation within rare disease drug development. Such unique collaborations would bring in new treatment options and further shape the market in the coming years.

Eli Lilly and Company, Bayer AG, Sanofi, Actelion Pharmaceuticals Ltd, Novartis AG, Celgene Corporation, AbbVie Inc., Johnson & Johnson Services, Inc., Alexion Pharmaceuticals, Inc., and Pfizer Inc among many others are some of the key players operating in the rare disease treatment market. 

Partial Chapter of the Table of Content 

Chapter 4   Rare Disease Treatment Market, By Drug Type

4.1    Key segment trends

4.2    Biologics

4.2.1    Market size, by region, 2015 - 2026 (USD Million)

4.3    Non-biologics

4.3.1    Market size, by region, 2015 - 2026 (USD Million)

Chapter 5   Rare Disease Treatment Market, By Therapeutic Area

5.1    Key segment trends

5.2    Cancer

5.2.1    Market size, by region, 2015 - 2026 (USD Million)

5.3    Blood-related Disorders

5.3.1    Market size, by region, 2015 - 2026 (USD Million)

5.4    Central Nervous System (CNS)

5.4.1    Market size, by region, 2015 - 2026 (USD Million)

5.5    Respiratory Disorders

5.5.1    Market size, by region, 2015 - 2026 (USD Million)

5.6    Musculoskeletal Disorders

5.6.1    Market size, by region, 2015 - 2026 (USD Million)

5.7    Cardiovascular Disorders

5.7.1    Market size, by region, 2015 - 2026 (USD Million)

5.8    Others

5.8.1    Market size, by region, 2015 - 2026 (USD Million)

Browse full table of contents (TOC) of this report @  https://www.gminsights.com/toc/detail/rare-disease-treatment-market